308846-06-2

Basic information

• Product Name: 2-Cyano-5-bromomethylpyridine
• Synonyms: 5-(BROMOMETHYL)PYRIDINE-2-CARBONITRILE;5-(bromomethyl)picolinonitrile;2-Cyano-5-bromomethylpyridine;5-(Bromomethyl)-2-cyanopyridine, 5-(Bromomethyl)picolinonitrile;2-cyano-5-broMide-Methyl pyridine;5-(broMoMethyl)-2-pyridinecarbonitrile;2-Pyridinecarbonitrile, 5-(broMoMethyl)-
• CAS NO: 308846-06-2
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.03
• Product Categories: Methyl Halides;Pyridines;Methyl Halides
• Mol File: 308846-06-2.mol

Chemical Properties

• Boiling Point: 329.5 ºC at 760 mmHg
• Flash Point: 153.1 ºC
• Appearance: /
• Density: 1.607 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.23±0.10(Predicted)
• CAS DataBase Reference: 2-Cyano-5-bromomethylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Cyano-5-bromomethylpyridine(308846-06-2)
• EPA Substance Registry System: 2-Cyano-5-bromomethylpyridine(308846-06-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 308846-06-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Cyano-5-bromomethylpyridine is used as a building block in organic synthesis for the preparation of various pharmaceutical and agrochemical products. Its unique structure allows for the creation of a wide range of compounds with potential applications in these fields.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Cyano-5-bromomethylpyridine is used as an intermediate in the production of active ingredients. Its presence in the synthesis process contributes to the development of new drugs with potential therapeutic benefits.
Used in Materials Science:
2-Cyano-5-bromomethylpyridine is also utilized in the field of materials science for the synthesis of polymers and other advanced materials. Its incorporation into these materials can enhance their properties and contribute to the development of innovative products with improved performance.
Overall, 2-Cyano-5-bromomethylpyridine is a valuable chemical compound with diverse applications in organic synthesis, pharmaceuticals, and materials science, making it of interest to researchers and scientists in various fields.

InChI:InChI=1/C7H5BrN2/c8-3-6-1-2-7(4-9)10-5-6/h1-2,5H,3H2

Upstream product

• 1620-77-5 5-methylpicolinonitrile 
• 128-08-5 N-Bromosuccinimide 
• 94-36-0 dibenzoyl peroxide 
• 3510-66-5 2-Bromo-5-methylpyridine 

Downstream Products

• 609345-79-1 5-(aminomethyl)pyridine-2-carboximidamide 
• 1351372-61-6 C₂₅H₂₄FN₃O 
• 1372174-97-4 N-((6-cyanopyridin-3-yl)methyl)-4-fluoro-N-(pentan-3-yl)benzenesulfonamide 
• 1372174-96-3 N-((6-cyanopyridin-3-yl)methyl)-4-chloro-N-(pentan-3-yl)benzenesulfonamide 
• 1372174-98-5 (S)-4-chloro-N-((6-cyanopyridin-3-yl)methyl)-N-(1-phenylpropyl)benzenesulfonamide 
• 1268245-15-3 5-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)cyclopropyl)picolinic acid 
• 1268245-14-2 4-((4-(2-(6-(1H-tetrazol-5-yl)pyridin-3-yl)cyclopropyl)-3-chlorophenoxy)methyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole 
• 1268245-86-8 C₂₀H₂₃ClN₂OSi 
• 181130-14-3 5-(aminomethyl)pyridine-2-carbonitrile 

Relevant articles and documents

Development of18F-Labeled Bispyridyl Tetrazines for In Vivo Pretargeted PET Imaging

Pretargeted PET imaging is an emerging and fast-developing method to monitor immunooncology strategies. Currently, tetrazine ligation is considered the most promising bioorthogonal reaction for pretargeting in vivo. Recently, we have developed a method to18F-label ultrareactive tetrazines by copper-mediated fluorinations. However, bispyridyl tetrazines—one of the most promising structures for in vivo pretargeted applications—were inaccessible using this strategy. We believed that our successful efforts to18F-label H-tetrazines using low basic labeling conditions could also be used to label bispyridyl tetrazines via aliphatic nucleophilic substitution. Here, we report the first direct18F-labeling of bispyridyl tetrazines, their optimization for in vivo use, as well as their successful application in pretargeted PET imaging. This strategy resulted in the design of [18F]45, which could be labeled in a satisfactorily radiochemical yield (RCY = 16%), molar activity (Am = 57 GBq/μmol), and high radiochemical purity (RCP > 98%). The [18F]45 displayed a target-to-background ratio comparable to previously successfully applied tracers for pretargeted imaging. This study showed that bispyridyl tetrazines can be developed into pretargeted imaging agents. These structures allow an easy chemical modification of18F-labeled tetrazines, paving the road toward highly functionalized pretargeting tools. Moreover, bispyridyl tetrazines led to near-instant drug release of iTCO-tetrazine-based ‘click-to-release’ reactions. Consequently,18F-labeled bispyridyl tetrazines bear the possibility to quantify such release in vivo in the future.

ANALOGUES OF PENTAMIDINE AND USES THEREFOR

The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

Modular Route to Azaindanes

A convergent radical based route to azaindanes is described, relying on the degenerative addition transfer of various substituted S-(pyridylmethyl)-O-ethyl dithiocarbonates (xanthates) to functional alkenes followed by radical cyclization onto the pyridine ring activated by protonation with trifluoroacetic acid. In one case, a richly decorated cyclohepta[b]pyridine could be assembled swiftly by allowing the first adduct to N-phenylmaleimide to undergo addition to N-allylphthalimide prior to cyclization.

A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.

NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS

The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

Novel FXR (NR1H4) binding and activity modulating compounds

The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

PYRIMIDODIAZEPINONE DERIVATIVE

The invention provides a pyrimidodiazepinone derivative represented by the general formula (I) [wherein n represents 1 or 2, Z represents a hydrogen atom or the like, R1 and R2 may be the same or different, and each represents a hydrogen atom or the like, A represents a bond, (CH2)m (wherein m represents an integer of 1 to 4), optionally substituted phenylene, optionally substituted pyridinediyl, or C=O, R3 represents a hydrogen atom, optionally substituted lower alkyl, or the like, and R4 represents a hydrogen atom or the like], or a pharmaceutically acceptable salt thereof or the like.

6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is -NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: Discovery of N-carboxymethyl-D-diphenylalanyl-L-prolyl[(5-amidino-2- thienyl)methyllamide

Thrombin, a crucial enzyme in the blood coagulation, has been a target for antithrombotic therapy. Orally active thrombin inhibitors would provide effective and safe prophylaxis for venous and arterial thrombosis. We conducted optimization of a highly efficacious benzamidine-based thrombin inhibitor LB30812 (3, Ki = 3 pM) to improve oral bioavailability. Of a variety of arylamidines investigated at the P1 position, 2,5-thienylamidine effectively replaced the benzamidine without compromising the thrombin inhibitory potency and oral absorption. The sulfamide and sulfonamide derivatization at the N-terminal position in general afforded highly potent thrombin inhibitors but with moderate oral absorption, while the well-absorbable N-carbamate derivatives exhibited limited metabolic stability in S9 fractions. The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (Ki = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively). This compound on a gravimetric basis was shown to be more effective than a low molecular weight heparin, enoxaparin, in the venous thrombosis models of rat and rabbit. Compound 22 (LB30870) was therefore selected for further preclinical and clinical development.